tbuckley/cabot-search huggingface dataset:
IMPACT OF VALVE TYPE (ROSS VS. MECHANICAL VALVE) ON HEALTH-RELATED QUALITY OF LIFE IN CHILDREN AND YOUNG ADULTS WHO HAVE UNDERGONE SURGICAL AORTIC VALVE REPLACEMENT
Authors: Daniel Beacher, Peter Frommelt, Cheryl L. Brosig, Jian Zhang, Pippa Simpson, Viktor Hraska, Salil Ginde
Journal: Journal of the American College of Cardiology (2020)
Resection of esophageal gastrointestinal stromal tumors.
Authors: Vladimir Trifanov, Oleg I Kit, Liubov Yu Vladimirova, Dmitriy Trifanov, Vadim Kasatkin
Journal: Journal of Clinical Oncology (2012)

e20503 Background: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of gastrointestinal tract. GISTs account for 0,1% to 0,3% of all tumors in the gastrointestinal tract. Two thirds of these tumors arise from the stomach, 25% arise from the small intestine and less than 5% arise from esophagus. Use of tyrosine kinase inhibitors has revolutionized therapy for GISTs but complete resection remains the treatment of choice. Methods: We report our experience (from 2005 to 2011) with five patients who underwent resection of esophageal GIST. Reviewed consensus management guidelines and performed a literature review for reported cases. Results: All five patients underwent surgery intervention at our institute. Four patients had no metastasis and they underwent tumor enucleation. Due to submucosal location only one of them was diagnosed with GIST by endoscopic biopsy before surgery. One patient had a giant liver metastasis invading totally all segments of right lobe of liver. He underwent transhiatal extirpation simultaneously combined with extended right-sided hemihepatectomy. That patient suffered from total dysphagia, 15 kg weight loss, gastrointestinal bleeding and a big lump in his right hypochondrium. After laparotomy we diagnosed big metastatic nodule invading the whole right lobe of liver 25 cm in diameter. After diaphragmotomy we diagnosed tumor of the lower third of esophagus. Consequently, we performed extended right-sided hemihepatectomy and transhiatal esophagus extirpation. Two months later esophageal plastics by means of ileocaecal segment of colon was performed. The pathological diagnosis was confirmed in all five cases by microscopic examination (KIT+; CD17+, mitotic rate). In adjuvant regime imatinib (400 mg/body/day) was administered for a year for all five patients. The patients are alive now, they were followed up every six months with CT for two years. Fortunately, no new tumors were observed during this period of time. Conclusions: Esophagectomy is the treatment of choice for esophageal GISTs but requires attention to operative details that emphasize complete en block excision of surrounding tissue and metastatic nodules.
BPI20-019: Pooled Analysis of Phase 3 Studies Comparing a Single-Dose Fixed Combination of Netupitant / Palonosetron (NEPA) vs a 3-Day Aprepitant-Based Regimen (APR) for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)
Authors: Rudolph M. Navari, Erminio Bonizzoni, Rita Wickham, Rebecca Clark-Snow
Journal: Journal of the National Comprehensive Cancer Network (2020)

"BPI20-019: Pooled Analysis of Phase 3 Studies Comparing a Single-Dose Fixed Combination of Netupitant / Palonosetron (NEPA) vs a 3-Day Aprepitant-Based Regimen (APR) for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)" published on 20 Mar 2020 by National Comprehensive Cancer Network.
HIGH ACCURACY OF CORONARY CTA IN LOW-INTERMEDIATE RISK TAVR EVALUATION
Authors: Vishak Kumar, Firehiwot Achamyeleh, Jennifer DoCampo, Joseph Krepp, Christian Nagy, Ramesh Mazhari, John Lichtenberger, Robert Zeman, James Earls, Jonathan Reiner, Andrew D. Choi
Journal: Journal of the American College of Cardiology (2020)
FASpecT/CT, A New SPECT/CT Acquisition With Higher Sensitivity and Efficiency in Radioiodine Thyroid Cancer Imaging
Authors: William T. Phillips, Vishal Kukkar, Gary L. Francis, Brandon C. Gorzell, Albert W. Cooper, Darlene F. Metter, Jack L. Lancaster
Journal: Clinical Nuclear Medicine (2020)

Purpose This article demonstrates the use of a new SPECT/CT acquisition protocol in patients with differentiated thyroid cancer (DTC). Methods SPECT/CT scans (FASpecT/CT) with fewer angle acquisitions were retrospectively reviewed in 30 DTC patients treated with radioiodine at University Hospital, San Antonio, Tex, from July 2017 to March 2019. This FASpecT/CT of 12 versus 60 to 64 sampled views for convention SPECT was made possible by iterative reconstruction. Results The FASpecT/CT protocol was judged to increase lesion detection in patients with low count rates. Furthermore, in patients with higher count rates, this technique reduced the acquisition time. FASpecT/CT patient images are shown as case examples in 4 of the 30 patients reviewed. Conclusions This FASpecT/CT acquisition in radioiodine-treated DTC offers the potential of higher sensitivity for metastatic lymph node detection in low count rates and a significant decrease in imaging time in high count rates. These advantages make SPECT/CT imaging more acceptable for patients who have difficulty with longer imaging times, to include the pediatric population.
Colon Sarcoidosis Mimicking Cancer at 18F-FDG PET/CT
Authors: Riccardo Mei, Irene Prediletto, Stefano Nava, Stefano Fanti, Valentina Ambrosini
Journal: Clinical Nuclear Medicine (2020)

Abstract This 68-year-old woman with a 9-year history of skin sarcoidosis presented with abdominal pain, bloating, and diarrhea. Following positive occult fecal blood, a diagnosis of ascending colon sarcoidosis was pathologically confirmed after colonoscopy. FDG PET/CT was performed for sarcoid staging, and the ascending colon demonstrated the only focal site of active sarcoidosis (SUVmax = 10).
Quantification of circulating endothelilial cells (CECs) as a predictor of response to chemotherapy with platinum and pemetrexed in patients with nonsquamous non-small cell lung carcinoma.
Authors: Alfredo Sanchez-Hernandez, Jose Garcia Sanchez, Remei Blanco, Sonia Maciá, Gaspar Esquerdo, Francisco Aparisi, Javier Garde, Silvia Catot, Jose Vidal, Francisco Garcia-Pinon, Oscar Juan
Journal: Journal of Clinical Oncology (2012)

e18053 Background: CECs play an important role in tumor neovascularisation and may have prognostic value in cancer patients (pts). The objective of this study is to assess the quantification of CECs as a predictor of response to chemotherapy (CT) in non-squamous NSCLC. Methods: 10ml of blood was obtained prior to the first, second and third cycle of CT in pts treated with platinum plus Pemetrexed. The quantification of CECs was undertaken using CellSearch technology in a central laboratory. The basal levels and the evolution of CECs was correlated with response to treatment according to RECIST criteria after 3 cycles of CT using analysis of variance (ANOVA). Results: Between July 2010 and June 2011 67 pts were included: 43 pts (64.2%) received CDDP/PEM and 24 (35.8%) received CBDCA/PEM. Median age: 60 years (range 40-82), 46 male (68,7%). Nine (13,4%) PS 0; 46 (68,7%) PS 1; 11 (16,4%) PS 2; 1 (1,5%) PS 3. Range of basal CECs: 8 - 1171 cel (median of 85 cel). CECs prior to cycle 2: median of 100 cel (range: 10-1388). CECs prior to ciclo 3: median of 94,5 cel (range: 5-1857). Response after 3 cycles was: 25 PR (36%), 17 SD (25%) and 16 PD (23%) and 11 NE (16%). In the analysis of variance, no significant relationship between the basal CEC count and response was found (p-value=0,831). Decrease &gt;50% between the 1 st and 2 nd cycle is correlated significantly with progression disease (p=0.026). Conclusions: In this homogeneous group of patients with NSCLC there is no correlation between response to treatment and basal levels of CECs. The decrease in CEC numbers after the first cycle could be a negative predictive factor. The correlation between the variations of CECs with PFS and OS will be presented during the conference.
Rash to mTOR inhibitor everolimus: Systematic review and meta-analysis.
Authors: Marigdalia K. Ramirez-Fort, Emily Christine Case, Alyx C. Rosen, Shenhong Wu, Mario E. Lacouture
Journal: Journal of Clinical Oncology (2012)

e19624 Background: Everolimus is an mTOR inhibitor approved for treatment of renal cell carcinoma, subependymal giant cell astrocytoma, and progressive neuroendocrine tumors of pancreatic origin. Its use may be hindered due to adverse events, including rash. The reported incidence and risk of rash to everolimus varies widely and has not been closely investigated. Therefore, we conducted a systematic review and meta-analysis of the literature to determine the incidence and risk of developing rash. Methods: We searched PubMed and Web of Science databases and abstracts presented at the American Society of Clinical Oncology from 1998 to July 2011 using the keyword “everolimus” to identify relevant clinical trials. Eligible studies included prospective phase II and phase III clinical trials of cancer patients on 10 mg of everolimus daily with available data on incidence of rash. The summary incidence and relative risk (RR) of rash were calculated using either the random-effects or fixed-effects model, depending on the heterogeneity of the constituent studies. Results: A total of 2,242 patients with various malignancies from 13 clinical trials were included in the analysis. The summary incidences of all-grade and high-grade rash in patients on everolimus were28.6% (95% CI: 20.8 – 38.0) and 1.0% (95% CI: 0.6 – 1.7), respectively. Everolimus was associated with a statistically significant increased risk of all-grade rash (RR=3.853, 95% CI: 2.470 – 6.013, p=0.000), but the RR for high-grade rash (RR= 2.997, 95% CI: 0.633 – 14.185) was not statistically significant, with a p value of 0.166. Conclusions: Everolimus is associated with a significant risk of developing rash. Management of rash to everolimus is critical to prevent dose modifications and decreased quality of life, both of which can negatively affect clinical outcomes.
Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomized in a chemotherapy phase III trial.
Authors: Adam Vilmar, Eric Santoni-Rugiu, Jens Benn Sorensen
Journal: Journal of Clinical Oncology (2012)

10617 Background: Platinum based doublets remain the cornerstone of treatment in non-small cell lung cancer (NSCLC) and often includes gemcitabine. A biomarker predicting sensitivity to this antimetabolite would represent a major step forward in the management of advanced disease. Ribonucleotide reductase subunit M1 (RRM1) has been of some value in NSCLC but evidence is not uniform. Accordingly, we explored the predictive role of RRM1 in patients with advanced NSCLC. Methods: 443 patients with advanced NSCLC were randomized in a phase III trial to regimen A (paclitaxel and cisplatin with gemcitabine) or regimen B (cisplatin and vinorelbine). Immunohistochemical evaluation of RRM1 was performed on mainly bioptic material and correlated to response rates, progression free survival (PFS) and overall survival (OS). Results: 261 (58.9%) patients had representative tissue samples for RRM1 evaluation. Disease control rate, PFS and OS were significantly improved in patients with RRM-negative tumors receiving regimen B as compared to patients with RRM-positive tumors (68.8% vs. 31.2%, P = 0.046 , 6.90 months (mths) (95% CI 5.83-7.96) vs. 3.93 mths (95% CI 3.11-4.76), P = 0.000 and 11.57 mths (95% CI 9.65-13.48) vs. 7.4 mths (95% CI 5.37-9.43), P = 0.002, respectively). However, this was not the case for patients receiving regimen A (67.6% vs. 32.4%, P = 0.366, 6.73 mths vs. 7.6 mths, P = 0.207, 11.07 mths vs. 12.37 mths, P = 0.103, respectively ). Together with histological subtype, RRM1-positivity emerged as the only other significant prognostic variable with a hazard ratio of 1.56 (95% CI 1.38-2.35, P = 0.033) in multivariate analysis for patients treated with regimen B. Conclusions: RRM1 protein expression was without predictive impact in patients treated with cisplatin, paclitaxel and gemcitabine. Surprisingly, the predictive power proved robust in the cisplatin and vinorelbine arm across classic endpoints confirmed by multivariate analysis. These findings may suggest that RRM1 is involved in vinorelbine sensitivity and warrant further research which will be presented shortly.
Successful classification of metastatic carcinoma of known primary using the CUPPRINT
Authors: H. M. Horlings, M. O. Warmoes, J. M. Kerst, H. Helgason, D. De Jong, L. Van ’t Veer
Journal: Journal of Clinical Oncology (2006)

20028 Background: It is critical for treatment decisions of metastatic disease to identify the primary tumor of the metastases, since the choice of optimal therapy depends on the correct diagnosis of the primary. Routine diagnostic evaluation is not sufficient to detect the primary site in 2–4% of all patients with pathology proven malignancy who present with metastatic disease. Currently the diagnostic yield is approximately between 20% and 30% for these patients. Microarray-based gene expression profiling has shown great promise to improve this. Methods: A microarray database was constructed of 497 frozen and 127 paraffin embedded (FFPE) samples representing 51 tumor types of both primary and metastatic tumors. The microarray database contained 22,000 gene-expression measurements for each sample. From the microarray database, we used an algorithm to search for gene combinations optimal for multi-tumor classification. This optimal gene-set was printed on 8-pack slides. These “1 × 3” glass slides contain eight mini-arrays with 1900 probes allowing for 8 simultaneous hybridizations, CUPPRINT. A k-nearest-neighbor-algorithm using this optimal gene-set was developed to discriminate between the 51 tumor types. We have independently verified the accuracy of this classification algorithm using FFPE samples from patients with metastases from 90 known and 50 unknown primary carcinomas. The expression data will be compared with clinicopathological data and an additional immunological panel of cytokeratin 7, cytokeratin 20, carcinogen embryonic antigen, CD 10, thyroid transcription factor 1, renal cell carcinoma, thyrogobulin, calcitonin, estrogen, progesterone, prostate specific antigen and CA 125. Results: The microarray based assay was able to classify correctly the primary site in 36 of 41 samples done so far (88% accuracy). The immunological panel showed a discriminative immunophenotype in 73% of these cases. For 49 known and 50 unknown primary tumors comparison between gene expression and clinicopathological investigations is currently pending. Conclusion: CUPPRINT, a microarrays based assay, is capable to accurately determine the tumor site of origin for a metastatic lesion. [Table: see text]
CHRONIC OBSTRUCTIVE PULMONARY DISEASE IS ASSOCIATED WITH INCREASED MORTALITY IN PATIENTS UNDERGOING MITRACLIP THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Chanavuth Kanitsoraphan, Jakrin Kewcharoen, Pattara Rattanawong, Chol Techorueangwiwat, Narut Prasitlumkum
Journal: Journal of the American College of Cardiology (2020)
HYPERCOAGULABLE STATE IN A PATIENT WITH ACUTE MYOCARDITIS AND ACUTE CORONARY SYNDROME RESULTING IN INTRA- AND EXTRA-CARDIAC THROMBOEMBOLISM
Authors: Varun Kohli, Lalith Namburu, Kajan Mahadevan, Ahad Khan, Tarun Bhandari, Vijay Ramu
Journal: Journal of the American College of Cardiology (2020)
SUDDEN PARADOXICAL DEVELOPMENT OF HEART FAILURE FOLLOWING PERICARDIOCENTESIS FOR CARDIAC TAMPONADE CALLED AS PERICARDIAL DECOMPRESSION SYNDROME (RARE, UNDERREPORTED CONDITION)
Authors: Austin Cusick, Amandeep Goyal, Poonam Bhyan, Lovely Chhabra
Journal: Journal of the American College of Cardiology (2020)
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study
Authors: Pau Montesinos, Gail J. Roboz, Claude-Eric Bulabois, Marion Subklewe, Uwe Platzbecker, Yishai Ofran, Cristina Papayannidis, Agnieszka Wierzbowska, Ho Jin Shin, Vadim Doronin, Stefan Deneberg, Su-Peng Yeh, Mehmet Ali Ozcan, Steven Knapper, Jorge Cortes, Daniel A. Pollyea, Gert Ossenkoppele, Sergio Giralt, Hartmut Döhner, Michael Heuser, Liang Xiu, Indrajeet Singh, Fei Huang, Julie S. Larsen, Andrew H. Wei
Journal: Leukemia (2020)
CAN YOU HEAR ME NOW? THE POTENTIAL OF MHEALTH TO GIVE CAREGIVERS A V-O-I-C-E ON THE CARDIOVASCULAR PATIENT CARE TEAM
Authors: Kellen Knowles, Alaa Diab, Helen Xun, Sharon Pang, Sunyoung Jang, Rohanit Singh, Francoise Marvel, Seth Shay Martin
Journal: Journal of the American College of Cardiology (2020)
Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma
Authors: Cavan P Bailey, Mary Figueroa, Achintyan Gangadharan, Yanwen Yang, Megan M Romero, Bridget A Kennis, Sridevi Yadavilli, Verlene Henry, Tiara Collier, Michelle Monje, Dean A Lee, Linghua Wang, Javad Nazarian, Vidya Gopalakrishnan, Wafik Zaky, Oren J Becher, Joya Chandra
Journal: Neuro-Oncology (2020)

Diffuse midline gliomas (DMG), including brainstem diffuse intrinsic pontine glioma (DIPG), are incurable pediatric high-grade gliomas (pHGG). Mutations in the H3 histone tail (H3.1/3.3-K27M) are a feature of DIPG, rendering them therapeutically sensitive to small-molecule inhibition of chromatin modifiers. Pharmacological inhibition of lysine-specific demethylase 1 (LSD1) is clinically relevant but has not been carefully investigated in pHGG or DIPG.Patient-derived DIPG cell lines, orthotopic mouse models, and pHGG datasets were used to evaluate effects of LSD1 inhibitors on cytotoxicity and immune gene expression. Immune cell cytotoxicity was assessed in DIPG cells pretreated with LSD1 inhibitors, and informatics platforms were used to determine immune infiltration of pHGG.Selective cytotoxicity and an immunogenic gene signature were established in DIPG cell lines using clinically relevant LSD1 inhibitors. Pediatric HGG patient sequencing data demonstrated survival benefit of this LSD1-dependent gene signature. Pretreatment of DIPG with these inhibitors increased lysis by natural killer (NK) cells. Catalytic LSD1 inhibitors induced tumor regression and augmented NK cell infusion in vivo to reduce tumor burden. CIBERSORT analysis of patient data confirmed NK infiltration is beneficial to patient survival, while CD8 T cells are negatively prognostic. Catalytic LSD1 inhibitors are nonperturbing to NK cells, while scaffolding LSD1 inhibitors are toxic to NK cells and do not induce the gene signature in DIPG cells.LSD1 inhibition using catalytic inhibitors is selectively cytotoxic and promotes an immune gene signature that increases NK cell killing in vitro and in vivo, representing a therapeutic opportunity for pHGG.1. LSD1 inhibition using several clinically relevant compounds is selectively cytotoxic in DIPG and shows in vivo efficacy as a single agent.2. An LSD1-controlled gene signature predicts survival in pHGG patients and is seen in neural tissue from LSD1 inhibitor-treated mice.3. LSD1 inhibition enhances NK cell cytotoxicity against DIPG in vivo and in vitro with correlative genetic biomarkers.
Reactivation of the Epicardium at the Origin of Myocardial Fibro-Fatty Infiltration During the Atrial Cardiomyopathy
Authors: Nadine Suffee, Thomas Moore-Morris, Bernd Jagla, Nathalie Mougenot, Gilles Dilanian, Myriam Berthet, Julie Proukhnitzky, Pascal Le Prince, David A. Tregouet, Michel Pucéat, Stéphane N. Hatem
Journal: Circulation Research (2020)

Fibro-fatty infiltration of subepicardial layers of the atrial wall has been shown to contribute to the substrate of atrial fibrillation.Here, we examined if the epicardium that contains multipotent cells is involved in this remodeling process.One hundred nine human surgical right atrial specimens were evaluated. There was a relatively greater extent of epicardial thickening and dense fibro-fatty infiltrates in atrial tissue sections from patients aged over 70 years who had mitral valve disease or atrial fibrillation when compared with patients aged less than 70 years with ischemic cardiomyopathy as indicated using logistic regression adjusted for age and gender. Cells coexpressing markers of epicardial progenitors and fibroblasts were detected in fibro-fatty infiltrates. Such epicardial remodeling was reproduced in an experimental model of atrial cardiomyopathy in rat and in Wilms tumor 1 (WT1)CreERT2/+;ROSA-tdT+/- mice. In the latter, genetic lineage tracing demonstrated the epicardial origin of fibroblasts within fibro-fatty infiltrates. A subpopulation of human adult epicardial-derived cells expressing PDGFR (platelet-derived growth factor receptor)-α were isolated and differentiated into myofibroblasts in the presence of Ang II (angiotensin II). Furthermore, single-cell RNA-sequencing analysis identified several clusters of adult epicardial-derived cells and revealed their specification from adipogenic to fibrogenic cells in the rat model of atrial cardiomyopathy.Epicardium is reactivated during the formation of the atrial cardiomyopathy. Subsets of adult epicardial-derived cells, preprogrammed towards a specific cell fate, contribute to fibro-fatty infiltration of subepicardium of diseased atria. Our study reveals the biological basis for chronic atrial myocardial remodeling that paves the way of atrial fibrillation.
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†
Authors: J. Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, H. Maxim Bruins, Theo M. De Reijke, Maria De Santis, Silke Gillessen, Nicholas James, Steven Maclennan, Juan Palou, Tom Powles, Maria J. Ribal, Shahrokh F. Shariat, Theo Van Der Kwast, Evanguelos Xylinas, Neeraj Agarwal, Tom Arends, Aristotle Bamias, Alison Birtle, Peter C. Black, Bernard H. Bochner, Michel Bolla, Joost L. Boormans, Alberto Bossi, Alberto Briganti, Iris Brummelhuis, Max Burger, Daniel Castellano, Richard Cathomas, Arturo Chiti, Ananya Choudhury, Eva Compérat, Simon Crabb, Stephane Culine, Berardino De Bari, Willem De Blok, Pieter J.L. De Visschere, Karel Decaestecker, Konstantinos Dimitropoulos, Jose L. Dominguez-Escrig, Stefano Fanti, Valerie Fonteyne, Mark Frydenberg, Jurgen J. Futterer, Georgios Gakis, Bogdan Geavlete, Paolo Gontero, Bernhard Grubmüller, Shaista Hafeez, Donna E. Hansel, Arndt Hartmann, Dickon Hayne, Ann M. Henry, Virginia Hernandez, Harry Herr, Ken Herrmann, Peter Hoskin, Jorge Huguet, Barbara A. Jereczek-Fossa, Rob Jones, Ashish M. Kamat, Vincent Khoo, Anne E. Kiltie, Susanne Krege, Sylvain Ladoire, Pedro C. Lara, Annemarie Leliveld, Estefania Linares-Espinós, Vibeke Løgager, Anja Lorch, Yohann Loriot, Richard Meijer, M. Carmen Mir, Marco Moschini, Hugh Mostafid, Arndt-Christian Müller, Christoph R. Müller, James N'Dow, Andrea Necchi, Yann Neuzillet, Jorg R. Oddens, Jan Oldenburg, Susanne Osanto, Wim J.G. Oyen, Luís Pacheco-Figueiredo, Helle Pappot, Manish I. Patel, Bradley R. Pieters, Karin Plass, Mesut Remzi, Margitta Retz, Jonathan Richenberg, Michael Rink, Florian Roghmann, Jonathan E. Rosenberg, Morgan Rouprêt, Olivier Rouvière, Carl Salembier, Antti Salminen, Paul Sargos, Shomik Sengupta, Amir Sherif, Robert J. Smeenk, Anita Smits, Arnulf Stenzl, George N. Thalmann, Bertrand Tombal, Baris Turkbey, Susanne Vahr Lauridsen, Riccardo Valdagni, Antoine G. Van Der Heijden, Hein Van Poppel, Mihai D. Vartolomei, Erik Veskimäe, Antoni Vilaseca, Franklin A. Vives Rivera, Thomas Wiegel, Peter Wiklund, Andrew Williams, Richard Zigeuner, Alan Horwich
Journal: European Urology (2019)
Metastatic Merkel Cell Carcinoma Resulting in Complete Heart Block
Authors: Brenden S. Ingraham, Kyle W. Klarich, Nandan S. Anavekar, Martha Grogan
Journal: JACC CardioOncology (2020)

Merkel cell carcinoma (MCC) is an aggressive, rare cutaneous neuroendocrine carcinoma that can metastasize to the heart in exceedingly rare cases. The incidence of MCC in the United States is 0.7 per 100,000 person-years with a median age of 75 to 80 years at diagnosis and a male predominance ([1][1